Cepheid与Oxford Nanopore Technologies合作推进基于自动测序的解决方案-动脉网

Cepheid and Oxford Nanopore Technologies Partner to Advance Automated Sequencingased Solutions

CISION 等信源发布 2025-04-09 19:00



可切换为仅中文







Collaboration to leverage Oxford Nanopore's sequencing platform and Cepheid's GeneXpert system to advance the field of sequencing for infectious diseases

合作利用牛津纳米孔公司的测序平台和Cepheid的GeneXpert系统，推动传染病测序领域的发展

OXFORD, United Kingdom

牛津，英国

and

和

SUNNYVALE, Calif.

加利福尼亚州桑尼维尔

，

April 9, 2025

2025年4月9日

/PRNewswire/ -- Oxford Nanopore Technologies, the company behind a new generation of sequencing-based molecular analysis technologies, and Cepheid, a leading molecular diagnostics company, today announced a strategic collaboration to develop and commercialize a seamless end-to-end workflow that combines Cepheid's GeneXpert system for pre-sequencing sample and library preparation with Oxford Nanopore's rapid, information-rich molecular analysis platform..

/PRNewswire/ -- 新一代基于测序的分子分析技术公司 Oxford Nanopore Technologies 与领先的分子诊断公司 Cepheid 今日宣布达成战略合作伙伴关系，共同开发并商业化一种无缝端到端工作流程，该流程将结合 Cepheid 的 GeneXpert 系统进行测序前样本和文库制备，以及 Oxford Nanopore 的快速、信息丰富的分子分析平台。

继续阅读

The two companies have completed a successful proof-of-concept study which demonstrated the feasibility of using Cepheid's cartridge-based GeneXpert system for sample and library preparation in a workflow with Oxford Nanopore's sequencing platform. The positive results from the proof-of-concept have paved the way for the strategic collaboration to develop and launch a joint Research Use Only.

这两家公司已经完成了一项成功的概念验证研究，该研究表明了在与牛津纳米孔测序平台结合的工作流程中，使用赛沛基于墨盒的GeneXpert系统进行样本和文库制备的可行性。概念验证的积极结果为战略合作伙伴关系铺平了道路，双方将合作开发并推出仅供研究使用的联合产品。

(RUO) workflow that will enable customers to leverage rapid, information-rich sequencing in-house for infectious disease analysis, returning results within hours instead of days.

(RUO) 工作流程，使客户能够利用快速、信息丰富的内部测序进行传染病分析，结果在数小时内返回，而不是数天。

Cepheid and Oxford Nanopore Technologies Partner to Advance Automated Sequencing-Based Solutions

Cepheid与Oxford Nanopore Technologies合作推进基于自动测序的解决方案

Post this

发布这个

The initial application of the workflow will focus on infectious disease, specifically the profiling of bacterial and fungal pathogens with whole genome sequencing first from culture isolates and eventually directly from positive blood cultures. The collaboration has the potential to expand from this initial application into additional infectious disease use cases, other areas such as cancer and human genetics, and eventually regulatory approved clinical diagnostics..

工作流程的初始应用将侧重于传染病，特别是通过全基因组测序对细菌和真菌病原体进行分析，首先从培养分离物开始，最终直接从阳性血培养物中进行。该合作有潜力从这一初始应用扩展到其他传染病用例、癌症和人类遗传学等其他领域，并最终扩展到获得监管批准的临床诊断。

'Combining the ease-of-use of the GeneXpert system, the most widely placed PCR diagnostic instrument world-wide, with Oxford Nanopore's unique sequencing platform, unlocks a richness of biomarker data that has historically been technically challenging for many labs to access,' said

“将全球最广泛使用的PCR诊断仪器GeneXpert系统的易用性与牛津纳米孔独特的测序平台相结合，解锁了历史上许多实验室在技术上难以获取的丰富生物标志物数据，”表示。

Vitor Rocha

维托尔·罗查

, President of Cepheid

，Cepheid总裁

. 'Providing an integrated solution to more effectively characterize infectious diseases, understand the epidemiology of bacterial outbreaks, and profile antimicrobial resistance will meaningfully accelerate our mission of expanding access to critical molecular information. The potential for future expansion of this technology to applications for patient care is exciting.'.

“提供一个综合解决方案，以更有效地表征传染病、了解细菌暴发的流行病学并分析抗菌素耐药性，将极大地加速我们扩大获取关键分子信息的使命。这项技术未来在患者护理应用方面的扩展潜力令人兴奋。”

The collaboration is intended to deliver a scalable, automated, end-to-end solution for simplified nanopore sequencing workflows for use within a range of settings, including labs that have previously not had the expertise to conduct sequencing in-house.

该合作旨在提供一个可扩展、自动化的端到端解决方案，以简化纳米孔测序工作流程，适用于多种环境，包括那些以前没有能力在内部进行测序的实验室。

'This collaboration represents an important step forward in delivering new and improved workflow options to better understand infectious diseases,' said

“这次合作代表了在提供新的和改进的工作流程选项方面迈出了重要的一步，以更好地了解传染病，”他说。

Dr.

博士

Gordon Sanghera

戈登·桑赫拉

, CEO of Oxford Nanopore Technologies

牛津纳米孔技术公司首席执行官

. 'By partnering to integrate our richer data, rapid insights, and accessible and affordable sequencing technology with Cepheid's GeneXpert architecture, we are establishing a workflow foundation that is positioned for future expansion into scaled routine clinical use.'

“通过合作，将我们更丰富的数据、快速的洞察力以及可及且价格合理的测序技术与Cepheid的GeneXpert架构整合在一起，我们正在建立一个工作流程基础，为未来扩展到大规模常规临床应用做好准备。”

The joint workflow will be compatible with a range of third-party informatics tools including Oxford Nanopore's EPI2ME, and other informatic solutions that are part of Oxford Nanopore's compatible provider network. Cepheid will also complement the joint workflow by directly offering an informatics solution, which they will commercialize by way of a license from a leading industry player; this informatics platform provides comprehensive pathogen identification, comprehensive antimicrobial resistance gene detection, SNP-based clonality for outbreak tracking and surveillance, and AI-driven genotypic antimicrobial susceptibility predictions..

该联合工作流程将兼容一系列第三方信息学工具，包括牛津纳米孔技术公司的 EPI2ME 以及其他作为牛津纳米孔技术公司兼容供应商网络一部分的信息学解决方案。Cepheid 还将通过直接提供一款信息学解决方案来完善这一联合工作流程，该解决方案将通过从行业领先企业获得的许可进行商业化；该信息学平台提供全面的病原体鉴定、全面的抗菌药物耐药基因检测、基于 SNP 的克隆性分析用于疫情追踪与监控，以及由人工智能驱动的基因型抗菌药物敏感性预测。

For Research Use Only. Not for use in diagnostic procedures

仅用于研究。不得用于诊断程序。

About Oxford Nanopore Technologies

关于牛津纳米孔技术

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing and the technology is in development for the analysis of other types of molecule including proteins.

牛津纳米孔技术公司的目标是通过使任何人、在任何地方都能分析任何事物，从而为社会带来最广泛的利益。该公司开发了一种基于纳米孔的新一代传感技术，可实现更快速、信息丰富、便捷且经济实惠的分子分析。其首个应用是DNA/RNA测序，该技术还正在开发用于其他类型分子（包括蛋白质）的分析。

The technology is used in more than 125 countries to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes.

该技术被用于125多个国家，以理解和表征人类和癌症、植物、动物、细菌、病毒以及整个环境的生物学特性。Oxford Nanopore Technologies的产品适用于分子生物学应用，不适用于诊断目的。

For more, visit: .

更多内容，请访问：。

https://nanoporetech.com/

About Cepheid

关于Cepheid

Based in

总部位于

Sunnyvale, Calif.

加利福尼亚州桑尼维尔

, Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation's Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases.

Cepheid是一家领先的分子诊断公司，是丹纳赫集团诊断平台旗下的运营公司。Cepheid致力于通过开发、制造和推广精确且易于使用的分子系统和测试来改善医疗保健。通过自动化高度复杂且耗时的手动流程，该公司的解决方案为各种规模的机构提供了一种更好的方法，以执行针对生物体和基因相关疾病的复杂基因检测。

Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit .

通过其强大的分子生物学能力，该公司正专注于那些最需要准确、快速和可操作的检测结果的应用领域，例如传染病和癌症的管理。欲了解更多信息，请访问。

http://www.cepheid.com

。

Media Contact:

媒体联系人:

media.communications@cepheid.com

媒体通讯@cepheid.com

SOURCE Cepheid and Oxford Nanopore Technologies

源头：Cepheid和Oxford Nanopore Technologies

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?